This sub-portfolio includes leading and prominent companies across pharmaceuticals, biotechnology, medical devices, and healthcare services. It targets well-established corporations with robust pipelines and proven track records in advancing healthcare. The portfolio balances high growth potential with stability by focusing on companies demonstrating steady performance while driving innovation. Diversified across global subsectors, it mitigates risks and aims for long-term capital appreciation, leveraging healthcare innovations to address trends like aging populations, rising chronic diseases, and increased technological integration.
Holdings 2024-11-22
